The K.G. Jebsen BTRC was one of the sponsors that supported a visit to Bergen (9-11 June, 2015) Dr. Robert Kerbel, a leading expert on angiogenesis. Dr. Kerbel is Professor in the Department of Medical Biophysics University of Toronto, Senior Scientist at the Sunnybrook Research Institute in Toronto, and a Canada Research Chair in Tumor Biology and Angiogenesis. He gave a top lecture “Antiangiogenic Therapeutics in Oncology: Overview, Update, and Future Directions”. After describing the main types of current antiangiogenic drug based therapies (over the last decade nine different antiangiogenic drugs has been approved for over ten different cancer indications), Dr. Kerbel analyzed possible causes of numerous failures of phase III clinical trials that involved antiangiogenic drugs, and summarized the most promising strategies for improving the efficacy of antiangiogenic treatment. At the end of the talk Dr. Kerbel presented some of his personal studies. This fascinating lecture was followed by an impressive discussion covered a broad range of questions from some specific issues of antiangiogenic therapy and its promising combination with immunotherapy, to the general perspectives of winning the war against cancer.
As a part of his scientific program in Bergen Dr. Kerbel visited the K.G. Jebsen BTRC to meet the BTRC director Professor Rolf Bjerkvig, who presented an overview of the research activities of the center. The fruitful discussion was focused on the development of improved, more translationally relevant, preclinical therapy models of advanced metastatic disease for evaluating antiangiogenic drug mechanisms and efficacy. It led to an agreement on establishing collaboration between the K.G. Jebsen BTRC and the Kerbel laboratory.
Oleg Tsinkalovsky, MD, PhD